Get a Free Consultation
Talk to an experienced patient coordinator for your hair transplant in Turkey.Key Takeaways
● CCCA must be medically controlled by a dermatologist before transplantation is considered.
● A cautious stability range is roughly 12–24 months without symptoms or progression.
● Trichoscopy, serial photographs and sometimes a scalp biopsy assess inflammatory activity.
● The occipital donor area must be examined too, never assumed healthy.
● Test grafting is advisable because graft survival in scar tissue is unpredictable.
The most important question before a CCCA hair transplant is not how many grafts can be placed. It is whether the inflammatory disease is truly inactive in both the recipient and donor scalp.
If you have watched your crown thin permanently, that distinction matters more than any surgical technique. A diagnosis of central centrifugal cicatricial alopecia does not automatically rule out transplantation. It does mean surgery must not proceed while inflammatory activity is suspected, because operating too early can put native and transplanted hair at risk.
This article provides general information and cannot determine whether an individual's CCCA is inactive or whether surgery is safe. Candidacy requires an in-person or appropriately documented assessment by a dermatologist and a qualified hair-transplant surgeon.
Can CCCA Ever Be Safely Transplanted?
A CCCA hair transplant may be possible when the disease has been medically controlled and objectively inactive for a sustained period, but it remains less predictable than transplantation for pattern hair loss. Surgery moves surviving follicles from the donor area, the scalp region where grafts are harvested, into the recipient area, the scarred zone receiving them.
A central centrifugal cicatricial alopecia hair transplant is not a cure. It does nothing to the inflammatory process underneath the scar. Cautious clinicians look for roughly 12–24 months without symptoms or documented progression, a practical convention drawn from specialist experience rather than a validated threshold.
Losing hair at the crown is not a cosmetic footnote. For many women it is a visible, daily loss, which is exactly why the timing question deserves a slow, evidence-led answer. Because CCCA-specific transplant evidence is sparse, the published literature does not support a universal graft-survival estimate.
Apparent stability does not make anyone automatically suitable. No waiting period, biopsy, trichoscopy finding or test graft can guarantee permanent inactivity or graft survival.
Possible candidate:
● No burning, itching, pain or tenderness over a sustained, documented period
● Serial photographs showing no expansion of the affected scalp across months
● No concerning inflammatory signs on trichoscopy; biopsy considered where uncertainty remains
● Occipital donor area clinically and trichoscopically unaffected on direct examination
● A dermatologist has documented the basis for judging the disease inactive
Not ready:
● Any current symptoms, scale, pustules, breakage or visible progression
● Uncertain or unconfirmed diagnosis; see a dermatologist before any surgical planning
● Perifollicular scale or perifollicular erythema in the recipient or donor scalp
● Recent treatment change, or medical control that has not yet settled
● No dermatologist currently monitoring the condition and interpreting findings
Candidacy rests on how the disease behaves rather than on how much hair is missing, so the next section explains why CCCA damages follicles in a way that ordinary thinning does not, and what that means for a surgeon planning grafts.
What Is CCCA and Why Does It Destroy Follicles Differently From Pattern Hair Loss?
CCCA differs from pattern hair loss because inflammation permanently destroys follicles and replaces them with scar tissue rather than merely miniaturising otherwise living follicles. That single difference reshapes every surgical decision that follows.
Definition: CCCA is a primary scarring alopecia that usually begins at the central scalp or vertex and expands centrifugally. In cicatricial alopecia, hair follicles are permanently destroyed. Fibrosis, the scar-like tissue that takes their place, cannot grow hair.
CCCA sits within the group of primary lymphocytic cicatricial alopecias, in which immune cells gather around the upper part of the follicle. Olsen and colleagues placed it in this category in the North American Hair Research Society workshop summary (Journal of the American Academy of Dermatology, 2003).
In pattern hair loss, follicles undergo miniaturisation: hairs grow finer and shorter, but the follicle survives. Permanent follicular destruction in CCCA removes the follicular openings, or ostia, the visible scalp pores where hairs emerge. Affected skin can look smooth and shiny as a result.
Accurate diagnosis matters because these conditions overlap. Callender and colleagues described hair breakage at the central scalp as an early or occult sign of CCCA (Archives of Dermatology, 2012), and breakage can sit alongside traction or the other causes of hair loss in women.
CCCA has multifactorial biology and mainly affects Black women and women of African descent, as the American Academy of Dermatology notes in its patient guidance. Malki and colleagues reported variants in the PADI3 gene in some patients (New England Journal of Medicine, 2019), which supports a genetic contribution rather than a single cause.
Painful, high-tension or symptom-provoking styling may be modified as part of care. That is different from saying styling caused the disease. CCCA is not a punishment for how you wear your hair.
Knowing the biology only takes you so far. The practical hurdle is proving that the inflammation behind the scarring has genuinely settled, which is where objective assessment replaces reassurance.
How Do Doctors Confirm CCCA Is Inactive Before Considering Surgery?
Doctors judge CCCA inactivity from sustained absence of symptoms and progression, serial examinations, trichoscopy and, when activity remains uncertain, a scalp biopsy. No single test guarantees permanent inactivity, so clinicians read the trend over time rather than one reassuring appointment.
Disease stability, in this context, means no new symptoms and no measurable spread across repeated assessments. Symptoms that suggest continuing inflammatory activity include itching, burning, tenderness, pain, scale, pustules, breakage and any outward spread of the bald area.
Serial clinical photography works as a time-lapse record of the scalp rather than a single snapshot. Dated images taken from the same angles, with consistent lighting and the same hair part, reveal slow expansion that neither you nor your doctor would notice month to month.
Five-point inactivity checklist:
● No burning, itching, pain or tenderness.
● No expansion on serial photographs.
● No inflammatory trichoscopic signs.
● No concerning donor-area findings.
● Biopsy not showing active inflammation when biopsy is indicated.
Documented inactivity is a prerequisite for discussion, not proof that surgery will be appropriate. If your symptoms, photographs, examination and trichoscopy disagree with each other, that disagreement is itself a reason to return to your dermatologist rather than book a procedure.
Biopsy, Trichoscopy and the Symptom-Free Interval Surgeons Look For
Inactivity cannot be confirmed by a single symptom-free visit, which is why objective assessment is layered on top of how the scalp feels. Two tools carry most of that weight.
Trichoscopy is magnified scalp examination using a dermatoscope or similar device. Miteva and Tosti described characteristic dermatoscopic features of CCCA, including a peripilar white or grey halo around hair shafts (Journal of the American Academy of Dermatology, 2014).
A pre-surgical trichoscopic assessment typically looks for perifollicular scale, perifollicular erythema, loss of follicular openings, white or fibrotic areas and variability in hair-shaft calibre. Findings are recorded separately for the recipient area and the donor area. Trichoscopy can show no concerning signs in the skin examined; it cannot prove that inflammation is absent everywhere.
A scalp biopsy helps most when history, examination and trichoscopy conflict. When the aim is to detect ongoing inflammation, a dermatologist may select a hair-bearing active-looking edge, often with trichoscopic guidance. A sample from the smooth centre of an end-stage scar may confirm fibrosis while telling you little about current activity.
Histopathology may show perifollicular lymphocytic inflammation, follicular destruction and fibrosis, with the picture depending on disease stage. Sperling and Sau laid much of that histological groundwork for central scalp scarring in Black patients (Archives of Dermatology, 1992). A negative biopsy samples only a small area, so it cannot exclude focal activity elsewhere.
Cautious clinicians then look for approximately 12–24 months without symptoms or visible progression. Treat this as an expert practice pattern used to reduce risk, not an internationally validated criterion. Disease extent, recent treatment changes, symptoms and objective findings all override a calendar figure, and your dermatologist should record the reasoning behind any stability decision before surgical planning starts.
Not sure whether your records show enough stability? Gather your biopsy report, medication history and dated scalp photographs, then use the WhatsApp button in the bottom-right corner for a free preliminary review. An online review cannot confirm inactivity, but it can flag which records or specialist checks may still be needed.
Documented quiet disease is usually the product of treatment that got it there. Knowing which options dermatologists commonly consider helps you understand what your own records should show before surgery is discussed.
How Do Dermatologists Get CCCA Under Control?
Dermatologists generally try to suppress CCCA inflammation with treatments such as topical or intralesional corticosteroids and, in selected patients, anti-inflammatory oral medicines before transplantation is considered. The aim of CCCA treatment before transplant is to stop inflammatory progression and protect the follicles you still have.
No treatment recreates follicles already replaced by scar. Choices depend on activity, extent, symptoms, other conditions and response, and the evidence base is limited, drawing largely on specialist experience and retrospective reports. Confirm every option below with your dermatologist rather than acting on a table.
Treatment category |
Purpose |
Important limitation |
|---|---|---|
High-potency topical corticosteroids |
Reduce inflammation in symptomatic scalp |
Need monitoring; cannot rebuild destroyed follicles |
Intralesional corticosteroids, such as intralesional triamcinolone |
Target inflammation at active-looking borders |
Local side effects possible; repeated sessions may be needed |
Tetracycline-class antibiotics, such as doxycycline |
Used for anti-inflammatory effect |
Prescription does not mean the scalp is infected |
Topical calcineurin inhibitors |
Non-steroid topical option in selected cases |
Limited CCCA-specific evidence; specialist guidance needed |
Systemic specialist medicines, such as hydroxychloroquine |
Considered in resistant or extensive disease |
Requires specialist supervision and safety monitoring |
Minoxidil as an adjunct |
May support surviving, non-scarred follicles |
Not anti-inflammatory; does not make CCCA inactive |
Intralesional and Topical Steroids, Doxycycline and Anti-Inflammatory Antibiotics, and Hair-Practice Changes
Treatment choices are individualised and must be confirmed with your treating dermatologist rather than started on the strength of an article. What follows describes options commonly discussed in specialist practice.
Herskovitz and Miteva described potent topical corticosteroids and intralesional triamcinolone as commonly used to calm perifollicular inflammation in CCCA (Clinical, Cosmetic and Investigational Dermatology, 2016). They remain the usual first step for local control, and your dermatologist decides whether either suits your scalp.
Doxycycline and other tetracycline-class antibiotics may be prescribed for their anti-inflammatory properties. Being offered one does not mean a bacterial infection has been found on your scalp.
Some patients are considered for hydroxychloroquine or topical calcineurin inhibitors under specialist supervision, usually where first-line treatment has not settled the disease. Minoxidil may support surviving follicles in non-scarred scalp, yet it has no anti-inflammatory action and does not replace dermatologist-directed treatment.
Hair-practice changes sit alongside medical treatment rather than instead of it. Traction-reducing styling, avoiding painful or high-tension styles, and easing back on chemical relaxers or high heat may reduce symptoms for some people. These are supportive measures, not a verdict on your hair choices.
Follow-up commonly continues after the scalp looks settled, because clinical symptoms and objective signs do not always change together. Book a dermatology review promptly if new pain, breakage, tenderness or expanding loss appears, and ask how often you should be seen while stability is being documented.
Do not start, stop or alter corticosteroids, antibiotics, hydroxychloroquine or other prescription treatments without your dermatologist's guidance.
Medical control is only half of the picture. The other half is what scarred scalp does to grafts placed into it, which is where expectations most often need adjusting.
What Are the Risks of Transplanting Into Scarred CCCA Scalp?
Transplanting into CCCA scar tissue carries a higher risk of uneven or poor graft growth because fibrosis may alter blood supply and because surgical trauma or natural disease recurrence may reactivate inflammation. Readers ask the blunt version of this: can you transplant hair into scar tissue CCCA has left behind?
Sometimes, under strict conditions. Scarred skin is a less predictable growing environment than healthy scalp, and CCCA-specific transplant evidence is limited.
Recipient-bed risks:
● Reduced vascularity in fibrotic tissue may lower graft survival
● Growth may be patchy or uneven across the recipient area
● Dense packing may overload a compromised recipient bed
Disease-related risks:
● Surgical trauma may provoke isomorphic, Koebner-type reactivation in susceptible scalp
● CCCA may reactivate independently of surgery, as part of its natural course
● Reactivated inflammation can damage native and transplanted follicles alike
Standard surgical risks:
● Infection, bleeding, delayed healing and donor-site scarring
● Poor or partial growth requiring further planning
● Unnatural distribution if the surgical design is inadequate
Reduced blood supply in fibrotic tissue is a biologically plausible concern rather than a measurement taken in each patient. The same applies to a Koebner-type response: broader cicatricial-alopecia literature raises it as a genuine worry, but its frequency in CCCA is not quantified.
Unger and colleagues, writing on the surgical treatment of cicatricial alopecia (Dermatologic Therapy, 2008), emphasised documented inactivity and cautious planning over choice of technique. Because published series are small and mixed, numerical survival or complication rates should not be presented to you as CCCA facts.
Most of that risk is managed through planning rather than skill alone, so the practical question becomes how a surgical plan should change once scarring alopecia is part of the diagnosis.
How Is a CCCA Hair Transplant Planned Differently?
A CCCA transplant is usually planned more conservatively, with donor verification, lower recipient density, possible staging and a small test-graft session before committing to broad coverage. The sequence below is the pathway most cautious teams follow before a CCCA hair transplant is scheduled.
1. Dermatologist documentation of the evidence supporting disease inactivity.
2. Recipient and donor trichoscopy performed and recorded.
3. Biopsy if uncertain, sampled from a hair-bearing active-looking border.
4. Test graft placed in a small, cosmetically non-critical area.
5. Growth and activity review before further surgery is offered.
6. Staged full procedure only if appropriate, based on that review.
A hair transplant for cicatricial alopecia is designed around the limits of the recipient bed, not around maximum graft numbers. Priorities shift toward cosmetic framing and softening the visible defect. Recreating pre-CCCA density is not the goal.
"In a fibrotic recipient bed, conservative density is a clinical judgement rather than a compromise. Fewer sites placed further apart put less demand on a blood supply we cannot measure directly, and a small test area shows us in months what a large session would take much longer to reveal." — Dr. Busra Yakupoglu, Hair Transplant Surgeon
For any suspected or confirmed scarring alopecia hair transplant, Medart Hair Transplant asks for dermatology records before surgical planning begins. International patients should supply biopsy reports, treatment records and dated serial photographs before travelling, so assessment rests on documented disease behaviour rather than a single set of photographs.
CCCA Transplant Readiness Checklist:
● Current symptoms: itching, burning, pain, tenderness, scale, pustules or breakage.
● Serial photographic stability: dated, comparable images showing no expansion.
● Trichoscopic activity signs: recipient-area findings recorded, not recalled.
● Biopsy status and findings: whether performed, site sampled, result.
● Duration without symptoms or progression: months documented rather than estimated.
● Current and previous medical treatment: drugs, response and recent changes.
● Occipital donor-area findings: density, calibre, scale, erythema, ostia.
● Test-graft recommendation: whether a small session should precede coverage.
● Follow-up and reactivation plan: who you contact, and how quickly.
Completing every line supports shared decision-making between you, your dermatologist and your surgeon. It does not guarantee candidacy or graft survival.
Is the Donor Area Itself Affected by CCCA? How Surgeons Verify an Unaffected Occipital Donor
The occipital donor area must be examined directly and never presumed unaffected, because CCCA can extend beyond the central scalp. A healthy appearance alone cannot prove that the donor area is suitable.
Donor verification typically records:
● Donor density and hair-shaft calibre across the occipital scalp
● Miniaturisation or marked variability in shaft diameter
● Hair breakage within the donor zone itself
● Perifollicular scale or perifollicular erythema on trichoscopy
● Loss of follicular openings, or white fibrotic areas
Density limits, safe harvesting margins and long-term supply are covered in more detail in our guide to how surgeons assess the hair-transplant donor area. If the CCCA donor area shows disease or another alopecia, harvesting may deepen visible thinning and yield unreliable grafts.
Tightly curled or Afro-textured hair often grows from curved follicles beneath the skin, so harvesting experience matters for extraction without transection. The technical side of transplantation of Afro-textured hair is covered separately, because technique cannot compensate for an inflamed donor zone.
Composite scenario: a woman with biopsy-confirmed CCCA has been symptom-free for 14 months. Recipient trichoscopy is reassuring and her photographs look stable. Donor trichoscopy tells a different story, showing perifollicular scale across the occipital scalp. Surgery is postponed and she returns to her dermatologist for reassessment and a possible donor biopsy.
Findings like that one carry weight. In my own practice, I postpone surgery for renewed burning or tenderness, perifollicular scale or erythema in either zone, expanding loss on photographs, suspicious donor-area changes, or biopsy evidence of active inflammation. That is clinical judgement applied to an individual scalp, not a universally proven rule.
A healthy-looking donor area cannot prove donor suitability in CCCA. Use the WhatsApp button in the bottom-right corner to share clear donor and recipient photographs for an initial surgical assessment, including guidance on whether trichoscopy or dermatology clearance should come first.
With donor health verified and a plan drafted, the remaining questions are the ones patients care about most: how much growth is realistic, and what happens if the disease wakes up afterwards.
What Results Can You Expect, and What Happens If CCCA Reactivates After Surgery?
A cautious pathway is to document at least 12–24 months without symptoms or progression and then assess a small test-graft area before undertaking a full CCCA hair transplant. Both intervals are practice conventions shaped by clinical judgement, not thresholds validated by large trials.
CCCA-specific transplant evidence is sparse and largely limited to small reports, alongside broader cicatricial-alopecia experience. Callender and colleagues reported hair transplantation in the surgical treatment of CCCA in a small group of patients (Dermatologic Surgery, 2014). That is why universal CCCA graft-survival or success percentages should not be quoted to you.
Timeline:
● 12–24 months: documented inactivity, treated as a cautious range rather than a validated rule.
● Test session: a small number of grafts placed in a cosmetically non-critical area.
● Approximately 9–12 months: assess growth and any inflammatory response.
● Full or staged surgery: considered only after acceptable test results.
● Long term: continued symptom monitoring with your dermatologist.
Earlier growth may be visible before nine months, though final judgement is usually premature. In practice, a CCCA inactive transplant decision rests on documented evidence rather than reassurance, and an acceptable test result says nothing definitive about how a larger or different recipient area will behave.
Composite scenario: another patient reaches 18 months of documented stability with a healthy occipital donor area. A CCCA test graft is placed behind the visible crown, reviewed at nine to twelve months, and staged coverage is discussed only once growth and scalp response are judged acceptable.
Realistically, the aim is possible cosmetic improvement and softer contrast between hair-bearing and scarred scalp. No waiting interval, biopsy result, trichoscopy finding or test graft can guarantee permanent inactivity or lifelong graft survival, and reactivation may occur independently of surgery.
New burning, itching, tenderness, scale, pustules or expanding loss should prompt dermatology review before surgery or after transplantation. New pain or central breakage deserves the same attention.
Candidacy rules differ sharply between hair-loss conditions, and assuming one set of rules covers all of them creates false reassurance. A side-by-side view makes the differences easier to hold onto.
How Does CCCA Compare With Traction Alopecia and Alopecia Areata for Transplant Candidacy? (Linked, Not Re-Explained)
CCCA requires evidence of inflammatory inactivity, while traction alopecia and alopecia areata have different candidacy tests and recurrence risks, as summarised below.
CCCA |
Traction alopecia |
alopecia areata transplant candidacy |
|
|---|---|---|---|
Activity test |
Symptoms, serial photographs, trichoscopy; biopsy if uncertain |
Clinical stability, traction history and examination; biopsy if diagnosis or scarring is uncertain |
Clinical examination, pull test/trichoscopy and dermatology assessment |
Stability wait |
Commonly 12–24 symptom- and progression-free months, as a cautious range rather than a validated threshold |
Commonly 12–24 months after traction stops and loss is demonstrably stable |
No universally safe waiting interval; recurrence remains unpredictable |
Typical graft survival expectation |
Variable and less predictable in fibrotic scalp; test graft advisable |
Often more favourable when permanently scarred loss is stable and donor hair is healthy |
Unpredictable because transplanted follicles may also be targeted |
First-line treatment |
Dermatologist-directed anti-inflammatory treatment |
Remove traction and modify the causative hair practice |
Dermatologist-directed medical treatment based on extent and severity |
Common Questions About CCCA Transplantation
Control the disease first. Document stability, verify that the donor scalp is genuinely unaffected, then consider a small test graft before broader coverage. For an honest CCCA hair transplant candidacy discussion, contact Medart Hair Transplant in Istanbul, Turkey through the WhatsApp button in the bottom-right corner. The team can review your history and surgical goals, though an in-person examination or dermatology clearance may still be required. The safest transplant plan begins with proving that CCCA is quiet, not with counting grafts.
References
- American Academy of Dermatology. Patient guidance on central centrifugal cicatricial alopecia and hair loss in Black women. https://www.aad.org
- Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia. Journal of the American Academy of Dermatology, 2003.
- Sperling LC, Sau P. The follicular degeneration syndrome in black patients: "hot comb alopecia" revisited and revised. Archives of Dermatology, 1992.
- Olsen EA, Callender V, McMichael A, et al. Central hair loss in African American women: incidence and potential risk factors. Journal of the American Academy of Dermatology, 2011.
- Callender VD, Wright DR, Davis EC, Sperling LC. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia. Archives of Dermatology, 2012.
- Miteva M, Tosti A. Dermatoscopic features of central centrifugal cicatricial alopecia. Journal of the American Academy of Dermatology, 2014.
- Malki L, Sarig O, Romano MT, et al. Variant PADI3 in central centrifugal cicatricial alopecia. New England Journal of Medicine, 2019.
- Herskovitz I, Miteva M. Central centrifugal cicatricial alopecia: challenges and solutions. Clinical, Cosmetic and Investigational Dermatology, 2016.
- Callender VD, Lawson CN, Onwudiwe OC. Hair transplantation in the surgical treatment of central centrifugal cicatricial alopecia. Dermatologic Surgery, 2014.
- Unger W, Unger R, Wesley C. The surgical treatment of cicatricial alopecia. Dermatologic Therapy, 2008.